Shell Asset Management Co. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,435 shares of the biopharmaceutical company’s stock after purchasing an additional 2,999 shares during the quarter. Shell Asset Management Co.’s holdings in Regeneron Pharmaceuticals were worth $5,565,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $346,000. Lord Abbett & CO. LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $51,931,000. Toronto Dominion Bank raised its holdings in Regeneron Pharmaceuticals by 25.8% in the 2nd quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after purchasing an additional 5,295 shares in the last quarter. WINTON GROUP Ltd bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $713,000. Finally, Public Employees Retirement System of Ohio raised its holdings in Regeneron Pharmaceuticals by 1.6% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after purchasing an additional 867 shares in the last quarter. Institutional investors and hedge funds own 67.40% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.81% during mid-day trading on Friday, hitting $432.98. 990,334 shares of the stock were exchanged. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The stock has a market cap of $45.91 billion, a PE ratio of 43.44 and a beta of 1.62. The stock’s 50 day moving average is $451.08 and its 200-day moving average is $456.76.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.94 EPS for the current year.
REGN has been the subject of several research reports. Leerink Swann restated a “positive” rating and issued a $552.00 price objective (down from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Piper Jaffray Companies restated an “overweight” rating and issued a $557.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group LLC restated a “hold” rating and issued a $500.00 price objective (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Finally, Robert W. Baird reiterated a “sell” rating and issued a $408.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, September 8th. Four analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $487.80.
In related news, SVP Robert E. Landry sold 526 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the sale, the senior vice president now owns 9,099 shares in the company, valued at $4,296,456.81. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,468 shares of company stock worth $42,312,448. Corporate insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.